MinervaX Hopes To Match Pfizer In Group B Streptococcus Vaccines Race
Raises €72m Ahead Of Phase III Program
The Danish biotech has secured more funding for a late-stage program to advance its vaccine against Group B streptococcus, which is in a race for approval with Pfizer's product.
You may also be interested in...
Private Company Edition: Quarter-over-quarter increases in venture capital have been bolstered by fewer but larger rounds, like the recent $245m series A for Aiolos. Also, OrbiMed raised $4.3bn across three new VC funds, Rampart completed an $85m series A and Atom Bioscience raised an $83m series D.
Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.
This year’s first designations under the European Medicines Agency’s priority medicines scheme have gone to a maternal vaccine for an infection in newborns and a treatment for an ultra-rare bone disorder.